Trial Profile
A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-05230907 IN SUBJECTS WITH INTRACEREBRAL HEMORRHAGE (ICH)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PF 5230907 (Primary)
- Indications Cerebral haemorrhage
- Focus Adverse reactions
- Sponsors Pfizer
- 04 Dec 2020 Results published in the Stroke
- 09 Feb 2018 Status changed from active, no longer recruiting to discontinued.
- 15 Dec 2017 Planned End Date changed from 18 Jun 2018 to 22 Jan 2018.